EDUARD TEIXIDOR VILA

Projectes

Precision Oncology in Girona

Estudio descriptivo y efecto del ritmo circadiano en el tratamiento con quimio-inmunoterapia neoadyuvante del cáncer del pulmón de célula no pequeña en estadios precoces. Un estudio multicéntrico con resultados de Real World Data (RWD)

Codi oficial: 2024_GECP_CMF Start date:01/12/2024 Data fi: 30/11/2026 Investigador/a principal: CLAUDIA MONTAÑES FERRER Organisme finançador: GRUPO ESPAÑOL DE CANCER DE PULMON

Publicacions

Precision Oncology in Girona , Cardiovascular Genetics , Medical Imaging

Sabaté-Ortega, J, Teixidor-Vilà, E, Sais, E, Hernandez-Martínez, A, Montañés-Ferrer, C, Coma, N, Polonio-Alcalá, E, Pineda, V, Bosch-Barrera, J

Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies

Frontiers in oncology, 2025, 15 dx.doi.org/10.3389/fonc.2025.1528950

Precision Oncology in Girona , Metabolism and Cancer

López, J, Llop-Hernández, A, Verdura, S, Serrano-Hervás, E, Martinez-Balibrea, E, Bosch-Barrera, J, Teixidor, E, López-Bonet, E, Martin-Castillo, B, Sardanyés, J, Alarcón, T, Lupu, R, Cuyàs, E, Menendez, JA

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

Cell Death Discovery, 2025, 11, 91-91 dx.doi.org/10.1038/s41420-025-02379-y

Metabolism and Cancer , Precision Oncology in Girona

Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493

Precision Oncology in Girona , Digestive diseases and microbiota

Sabaté-Ortega, J, Albert-Carrasco, M, Escribano-Ferrer, C, Grau-Manrubia, G, Fina-Planas, C, López-Núnez, C, Teixidor-Vilà, E, Bujons-Buscarons, E, Montañés-Ferrer, C, Sala-González, N

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Frontiers in oncology, 2024, 14, 1354127-1354127 dx.doi.org/10.3389/fonc.2024.1354127

Metabolism and Cancer , Precision Oncology in Girona

Cuyàs E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Hervás E, Llop-Hernández À, Teixidor E, Bosch-Barrera J, López-Bonet E, Martin-Castillo B, Lupu R, Pujana MA, Sardanyès J, Alarcón T, Menendez JA

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Cell Death Discovery, 2024, 10, 417-417 dx.doi.org/10.1038/s41420-024-02184-z

Descriptive epidemiology, genetics and cancer prevention , Precision Oncology in Girona , Metabolism and Cancer

Teixidor-Vilà E, Trallero J, Puigdemont M, Vidal-Vila A, Hernandez-Martínez A, Sais E, Sabaté-Ortega J, Verdura S, Menendez JA, Bosch-Barrera J, Sanvisens A, Marcos-Gragera R

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.

LUNG CANCER, 2024, 197, 107995-107995 dx.doi.org/10.1016/j.lungcan.2024.107995

Precision Oncology in Girona , Radiation Oncology and Medical Physics of Girona

Sais, E, PLUJA, A., MONTAÑES, C., Bujons-Buscarons, E, PINEDA, F., Iguaran A, Roselló À, Hernández Martínez A, Teixidor-Vilà, E, ROMERA, A., Bosch-Barrera, J, ERASO, A., Oliva-Poch E

1062P Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy

ANNALS OF ONCOLOGY, 2024, 35, 1-1 dx.doi.org/10.1016/j.annonc.2024.08.1120

Precision Oncology in Girona , Metabolism and Cancer

Teixidor-Vilà, E, Verdura, S, JA Encinar, Llop-Hernández À, Sais, E, Hernández Martínez A, ROMERA, A., Brunet JM, Martin-Castillo B, Lopez-Bonet, E, Bosch-Barrera, J, Cuyàs, E, Menendez, JA

1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy

ANNALS OF ONCOLOGY, 2024, 35, 697-697 dx.doi.org/10.1016/j.annonc.2024.08.1097

Precision Oncology in Girona , Metabolism and Cancer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Descriptive epidemiology, genetics and cancer prevention , Precision Oncology in Girona , Medical Imaging , Metabolism and Cancer , Haematology

Bosch-Barrera, J, Teixidor, E, Sanvisens, A, Puigdemont, M, Trallero, J, Vila, AV, Osca, G, Roberte, MV, Priego, N, Sais, E, Martínez, AH, Ortega, JS, Cuyàs, E, Verdura, S, Puig, J, Pineda, V, Martí-Navas, M, Calvo, A, Menendez, JA, Marcos-Gragera, R, Valiente, M

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

JOURNAL OF THORACIC ONCOLOGY, 2023, 18, 426-427

Directori

Projectes

Publicacions

Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies

Mitochondrial priming and response to BH3 mimetics in "one-two punch" senogenic-senolytic strategies

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.

1062P Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy

1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

Formulari de contacte

About IDIBGI!